2025-04-01 2026-03-31 false Capium Accounts Production 1.1 14712128 2025-04-01 2026-03-31 14712128 bus:FullAccounts 2025-04-01 2026-03-31 14712128 bus:FRS102 2025-04-01 2026-03-31 14712128 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 14712128 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 14712128 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 14712128 2025-04-01 2026-03-31 14712128 2026-03-31 14712128 bus:RegisteredOffice 2025-04-01 2026-03-31 14712128 core:WithinOneYear 2026-03-31 14712128 core:AfterOneYear 2026-03-31 14712128 1 2025-04-01 2026-03-31 14712128 bus:Director1 2025-04-01 2026-03-31 14712128 bus:Director1 2026-03-31 14712128 bus:Director1 2024-04-01 2025-03-31 14712128 2024-04-01 14712128 bus:LeadAgentIfApplicable 2025-04-01 2026-03-31 14712128 2024-04-01 2025-03-31 14712128 2025-03-31 14712128 core:WithinOneYear 2025-03-31 14712128 core:AfterOneYear 2025-03-31 14712128 bus:EntityAccountantsOrAuditors 2024-04-01 2025-03-31 14712128 core:CostValuation core:Non-currentFinancialInstruments 2026-03-31 14712128 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 14712128 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2026-03-31 14712128 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2026-03-31 14712128 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-03-31 14712128 core:Non-currentFinancialInstruments 2026-03-31 14712128 core:Non-currentFinancialInstruments 2025-03-31 14712128 core:ShareCapital 2026-03-31 14712128 core:ShareCapital 2025-03-31 14712128 core:RetainedEarningsAccumulatedLosses 2026-03-31 14712128 core:RetainedEarningsAccumulatedLosses 2025-03-31 14712128 dpl:Item1 2025-04-01 14712128 dpl:Item1 2026-03-31 14712128 dpl:Item1 2024-04-01 14712128 dpl:Item1 2025-03-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14712128
England and Wales

 

 

 

RAYSON PHARMA CO. LTD


Unaudited Financial Statements
 


Period of accounts

Start date: 01 April 2025

End date: 31 March 2026
 
 
Notes
 
2026
£
  2025
£
Current assets      
Debtors 3 142    1,328 
Cash at bank and in hand 894    6,152 
1,036    7,480 
Creditors: amount falling due within one year 4 (241,035)   (139,968)
Net current assets (239,999)   (132,488)
 
Total assets less current liabilities (239,999)   (132,488)
Net assets (239,999)   (132,488)
 

Capital and reserves
     
Called up share capital 1    1 
Profit and loss account (240,000)   (132,489)
Shareholders' funds (239,999)   (132,488)
 


For the year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 04 November 2026 and were signed by:


-------------------------------
Mr Meisam Parsanejad
Director
1
General Information
RAYSON PHARMA CO. LTD is a private company, limited by shares, registered in England and Wales, registration number 14712128, registration address Jubilee House 3 The Drive, Great Warley, Brentwood, Essex, England, CM13 3FR.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
2.

Average number of employees

Average number of employees during the period was 1 (2025 : 1).
3.

Debtors: amounts falling due within one year

2026
£
  2025
£
VAT Input 142    1,328 
142    1,328 

4.

Creditors: amount falling due within one year

2026
£
  2025
£
Kiyan pay 215,354    132,154 
PAYE & NI payable 13,745    3,105 
Wages & Salaries Control Account 600    0 
Director's Remuneration Payable 5,156    0 
Accounting fee payable 200    0 
Directors' Current Accounts 5,980    4,709 
241,035    139,968 

2